Search

Search Results

• 

  The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus

  Fulvia Ceccarelli, Matteo Piga, Alessandra Bortoluzzi, Laura Coladonato, Micaela Fredi, Daniele Mauro, Chiara Tani, Luca Iaccarino

  23-07-2025

  https://doi.org/10.4081/reumatismo.2025.1830

  1339

  PDF: 73

• PO:16:236 | Achieving a low disease activity state with a corticosteroid dose of 5 mg or less: observational study with anifrolumab in patients with systemic lupus erythematosus in Italy Alessandra Bortoluzzi¹, Fulvia Ceccarelli², Fabio Leo³, Paola Roccatagliata³, Chiara Tani⁴, Margherita Zen⁵ | ¹Azienda Ospedaliera Universitaria Sant' Anna di Cona, Università di Ferrara Italy; ²Unità di Reumatologia, Università Sapienza Roma Italy; ³AstraZeneca S.p.a. Milano Italy; ⁴Università di Pisa e Azienda Ospedaliero Universitaria Pisana, Pisa Italy; ⁵Dipartimento di Medicina DIMED , Divisione di Reumatologia, Università di Padova, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2163

  65

• PO:14:202 | Use of anifrolumab in the treatment of the hematological manifestations of systemic lupus erythematosus: a single-centre case series Gaia Ferracane^1|2, Jessika Dichiara^1|2, Elena Manna^1|2, Lorenzo Mattia Bianchessi^1|2, Giovanni Zanframundo^1|2, Serena Bugatti^1|2, Veronica Codullo^1|2, Lorenzo Cavagna^1|2, Francesca Bottazzi^1|2 | ¹Department of Internal Medicine and Therapeutics, Università di Pavia; ²Division of Rheumatology, IRCCS Policlinico San Matteo, Pavia, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2159

  104

• PO:10:149 | Efficacy of anifrolumab in a case of systemic lupus erythematosus with pulmonary involvement Fabio Brandolino¹, Giulia Pazzola¹, Luca Ronzoni³, Andreina Teresa Manfredi^1|2, Carlo Salvarani^1|2 | ¹SC Reumatologia, IRCCS Arcispedale Santa Maria Nuova, AUSL Reggio Emilia; ²Università di Modena e Reggio Emilia, Scuola di specializzazione in Reumatologia, Modena; ³SC Malattie dell'Apparato Respiratorio, IRCCS Arcispedale Santa Maria Nuova, AUSL Reggio Emilia, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2146

  95

• PO:14:203 | Impact of anifrolumab on depressive symptoms in systemic lupus erythematosus: results from a single-centre prospective observational study Luca Moroni¹, Biancamaria Venerandi¹, Maria Cilona¹, Anna Vivona¹, Gabriele Gallina¹, Giovanni Benanti¹, Enrica Bozzolo¹, Giuseppe Ramirez¹, Marco Matucci-Cerinic¹, Lorenzo Dagna¹. | ¹U.O. di Immunologia, Reumatologia, Allergologia e Malattie Rare - IRCCS Ospedale San Raffaele, Milano, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2032

  67

• CO:11:2 | Systemic lupus erythematosus with major neuropsychiatric involvement treated with anifrolumab: literature review and a case report Giulia Rizzo¹, Fabio Congiu¹, Elisabetta Chessa², Marta Paola Pireddu¹, Elena Ragusa¹, Alessandra Oliva¹, Marianna Salis¹, Alberto Cauli^1|2, Matteo Piga^1|2 | ¹SC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università di Cagliari Italy; ²SC Reumatologia, AOU Cagliari Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2120

  111

• PO:25:079 | Anifrolumab in refractory dermatomyositis: a case report Chiara Calabrese¹, Corrado Campochiaro^1|2, Giacomo De Luca ^1|2, Veronica Batani¹, Marco Matucci-Cerinic^1|2, Lorenzo Dagna ^1|2 | ¹Dipartimento di Reumatologia e Scienze Mediche, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO Milano; ²Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica e Trapianti, Milano, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2190

  91

• PO:18:271 | Managing concomitant sle and psoriasis: the role of anifrolumab in a clinical case Angela Carenza¹, Liliana Dinoia², Sergio De Gioia², Federica Gatti¹, Teresa Caferri¹, Lucia Cristiana Colaprico¹, Angelica Napoletano¹, Giuseppe Lopalco¹, Florenzo Iannone¹. | ¹Rheumatology Unit, University of Bari, Department of Precision and Regenerative Medicine, Jonian area ^DiMePRe-J, Bari, Italy; ²Azienda Sanitaria Locale di Taranto, presidio ospedaliero SS. Annunziata, Unità Operativa di Reumatologia, Taranto, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2047

  71

• PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli^1|2, Chiara Tani¹, Luca Moroni³, Filippo Vesentini⁴, Francesca Bottazzi⁵, Micaela Fredi⁶, Ettore Silvagni⁷, Matteo Piga⁸, Flavia Riccio⁹, Fulvia Ceccarelli¹⁰, Ginevra De Marchi¹¹, Edoardo Biancalana¹², Gianluca Moroncini¹³, Rita Mulè¹⁴, Mariele Gatto¹⁵, Laura Coladonato¹⁶, Paola Conigliaro¹⁷, Maria Gerosa¹⁸, Andrea Picchianti Diamanti¹⁹, Benedetta Bianchi²⁰, Federica Maiolini²⁰, Michela Gasparotto²⁰, Serena Guiducci²⁰, Maria Ilenia De Andres²⁰, Alberto Lo Gullo²⁰, Silvia Noviello²⁰, On Behalf Of The Reveal Investigators²⁰, Marta Mosca¹. | ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; ²Department of Medical Biotechnologies, University of Siena, Siena; ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; ⁴Rheumatology Unit, Department of Medicine, University of Padua, Padova; ⁵Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; ⁶Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; ⁷Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; ⁸Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari;  ⁹Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; ¹⁰Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; ¹¹Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; ¹²Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; ¹³Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; ¹⁴Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; ¹⁵Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; ¹⁶Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; ¹⁷Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; ¹⁸Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; ¹⁹Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; ²⁰Italian REVEAL Study Group Italy, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2031

  81

• PO:18:276 | Use of anifrolumab in the treatment of difficult-to-treat manifestations in systemic lupus erythematosus Antonella Grimaldi¹, Giuseppe Alessandrini², Laura Quarta¹, Maria Rita Ricciardi¹, Daniela Costanza¹, Clara Minerba¹, Eugenio Quarta¹ | ¹UOC Reumatologia Verona; ²Specialista Dermatologo in Libera Professione, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2170

  95

• PO:16:235 | Anifrolumab in systemic lupus erythematosus: real-life experience of a single-center cohort Filippo Vesentini¹, Luca Iaccarino¹, Federico Arru², Greta Hulej¹, Anna Giorgia Osele¹, Noemi Merra¹, Davide Ragno¹, Andrea Doria¹, Margherita Zen¹ | ¹UOC Reumatologia, Dipartimento di Medicina DIMED, Università degli Studi di Padova; ²UO Medicina, ASL 3 Nuoro, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2162

  74

• PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort Fabio Congiu¹, Elisabetta Chessa², Giulia Rizzo¹, Elena Ragusa¹, Marta Paola Pireddu¹, Alessandra Oliva¹, Marianna Salis¹, Mattia Congia², Maria Maddalena Angioni¹, Micaela Rita Naitza¹, Alberto Floris², Alberto Cauli^1|2, Matteo Piga^1|2 | ¹AOU e Università degli studi di Cagliari; ²SC Reumatologia PO Duilio Casula, Cagliari, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2167

  87

• PO:16:231 | Differential clinical features of systemic lupus erythematosus patients on biological therapies: insights from a monocentric cohort Pietro Francesco Pilo, Elisa Bellis, Claudia Garulli, Claudio Cruciani, Marta Saracco, Claudia Lomater, Elena Marucco, Gloria Crepaldi, Valeria Data, Annamaria Iagnocco, Mariele Gatto. | Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Torino, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2043

  74